|
|
|
JNCE - Jounce Therapeutics, Inc
Jounce Therapeutics Inc. (JNCE) is a clinical stage immunotherapy company that is engaged in discovering and developing novel cancer immunotherapies. The company focuses on developing therapies that enable the immune system to attack tumors and provide long-lasting benefit to patients. Jounce Therapeutics' proprietary platform allows for the identification of unique and clinically relevant targets for T cell activation.
Jounce Therapeutics has a pipeline of product candidates, with its lead product candidate, JTX-8064, being developed for the treatment of solid tumors. The company is also developing a number of other product candidates, including JTX-1811 for the treatment of ovarian cancer, JTX-4014 for the treatment of head and neck cancer, and JTX-8931 for the treatment of acute myeloid leukemia.
The company's technology platform is based on the identification of unique and clinically relevant targets for T cell activation. This platform includes the use of computational biology, bioinformatics, and other techniques to identify targets that are highly expressed on tumor cells but not on healthy tissue. Jounce Therapeutics' approach is designed to minimize toxicity and increase the durability of response for patients.
Jounce Therapeutics was founded in 2013 and is headquartered in Cambridge, Massachusetts. The company is led by a team of experienced biotech executives with a track record of success in developing and commercializing novel therapies.
|
|
|
|
|
